AURAGuides › Palindromic rheumatism vs rheumatoid arthritis
Palindromic rheumatism vs rheumatoid arthritis
They share blood markers, they share joints, and one sometimes becomes the other. But day to day they behave very differently, and the difference is mostly about what happens between flares.
By Peter Barnett, who makes Aura · Updated 25 October 2026 · Not medical advice
The short answer
- Rheumatoid arthritis (RA) is persistent: inflammation sticks around and, untreated, can damage joints.
- Palindromic rheumatism (PR) comes in attacks that resolve completely, with normal joints and normal X-rays in between.
- Many people with PR test positive for the same antibodies as RA, and somewhere between a tenth and two-thirds go on to develop it, depending on the study.
Side by side
| Palindromic rheumatism | Rheumatoid arthritis | |
|---|---|---|
| Pattern | Sudden attacks, usually lasting under three days, then gone | Ongoing inflammation that flares and settles but rarely clears |
| Joints per attack | Usually one, sometimes two or three, often a different one each time | Typically several at once, often the same joints on both sides |
| Between flares | Joints normal; inflammation markers usually normal | Stiffness, swelling or tenderness commonly persist |
| X-rays | Normal, even after years | Erosions can develop if inflammation is not controlled |
| RF / anti-CCP | Positive in roughly 40–70% in most series | Positive in most people |
| Usual treatment | NSAIDs for attacks; hydroxychloroquine to reduce them | Disease-modifying drugs such as methotrexate, started early |
PR figures are from the reviews listed below.1 RA is described in general terms; every person's disease is different.
Why they are linked
Rheumatoid factor and anti-CCP antibodies, the two blood markers most associated with RA, turn up in somewhere between 39% and 68% of people with palindromic rheumatism in most published series.1 Nearly one in five people with established RA report having had palindromic attacks before it settled in.1 That overlap is why researchers increasingly treat PR as an early point on the RA continuum, while noting that its imaging and clinical picture suggest the underlying process is not identical.2
How often does PR become RA?
Published figures range from 10% to 66%, which mostly reflects differences in who was studied, for how long, and on what treatment.1 Two examples:
- In a Canadian series, 29 of 61 people (48%) had developed RA after an average of 5.4 years, and 83% of them had been anti-CCP positive at the start.3
- In a Barcelona series, 22% had developed RA after an average of 7.6 years. Progression was more common in anti-CCP-positive people (30% against 15%), but most antibody-positive people still had not developed RA.4
Where it does happen, it tends to happen early: in one analysis the median time from the first palindromic attack to RA was about 1.2 years.1 Antimalarial treatment has been associated with slower and less frequent progression in an observational study, though not proven to prevent it.5
What to watch for
Without suggesting anyone diagnose themselves, these are the kinds of change worth raising with your rheumatologist rather than waiting for the next routine appointment:
- attacks that last noticeably longer than they used to, or stop resolving completely;
- joints that stay stiff or swollen between attacks;
- more joints involved at once, or the same joints on both sides together;
- attacks becoming much more frequent.
Each of those is easier to spot, and much easier to describe, with a record kept over months. See how to keep a flare diary and how to prepare for a rheumatology appointment.
This page summarises published research for general information. It is not medical advice, and it is no substitute for a rheumatologist who knows your history.
Sources
- Sanmartí R, Frade-Sosa B, Morlà R, et al. Palindromic rheumatism: just a pre-rheumatoid stage or something else? Front Med 2021;8:657983. doi:10.3389/fmed.2021.657983
- Mankia K, Emery P. Palindromic rheumatism as part of the rheumatoid arthritis continuum. Nat Rev Rheumatol 2019;15:687–695. doi:10.1038/s41584-019-0308-5
- Russell AS, Devani A, Maksymowych WP. The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palindromic rheumatism to rheumatoid arthritis. J Rheumatol 2006;33:1240–1242. PubMed 16724377
- Sanmartí R, Cabrera-Villalba S, Gómez-Puerta JA, et al. Palindromic rheumatism with positive anticitrullinated peptide/protein antibodies is not synonymous with rheumatoid arthritis. J Rheumatol 2012;39:1929–1933. doi:10.3899/jrheum.120568
- Gonzalez-Lopez L, Gamez-Nava JI, Jhangri G, et al. Decreased progression to rheumatoid arthritis or other connective tissue diseases in patients with palindromic rheumatism treated with antimalarials. J Rheumatol 2000;27:41–46. PubMed 10648016